Lippman Evan
- SEC CIK
- 0002062834
In the past year, 2 open-market sale filings worth $2.16M and no purchases.
Current role at each company
- TEVA Teva Pharmaceutical Industries LtdEVP, Business Developmentas of Aug 19, 2026
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- $2.16M
- 2 filings
- Net
- −$2.16M
- Bought minus sold
- Companies
- 1
- With open-market trades
Trades
Every Form 4 that lists Lippman Evan as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 19, 2026 (view filing)4:00 PM ET | Aug 17 | 2 days | Lippman EvanEVP, Business Development | SSale | −18.6K | $36.57 | −$680.3K | −42.1%25.6K after | 10b5-1 |
| May 18, 2026 (view filing) | May 14 | 4 days | Lippman EvanEVP, Business Development | SSale | −41.7K | $35.58 | −$1.48M | −48.5%44.2K after | 2 lots10b5-1 |